Gilead develops solid tumour cell therapy with Gadeta

Gilead is making a mark with its Yescarta cell therapy in blood cancer, but like its rivals the California pharma is trying to find ways to get this approach to work in solid tumours. With this in mind Gilead’s subsidiary Kite has signed a deal with …